Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo.
about
Expression and regulation of GFRalpha3, a glial cell line-derived neurotrophic factor family receptorGDNF Overexpression from the Native Locus Reveals its Role in the Nigrostriatal Dopaminergic System FunctionComparative Analysis of the Effects of Neurotrophic Factors CDNF and GDNF in a Nonhuman Primate Model of Parkinson's DiseaseGDNF-based therapies, GDNF-producing interneurons, and trophic support of the dopaminergic nigrostriatal pathway. Implications for Parkinson's diseaseCalcitriol protects against the dopamine- and serotonin-depleting effects of neurotoxic doses of methamphetamineThe candidate neuroprotective agent artemin induces autonomic neural dysplasia without preventing peripheral nerve dysfunctionDopamine neuron stimulating actions of a GDNF propeptideDelayed infusion of GDNF promotes recovery of motor function in the partial lesion model of Parkinson's disease.GDNF reverses priming for dyskinesia in MPTP-treated, L-DOPA-primed common marmosets.Aging reveals a role for nigral tyrosine hydroxylase ser31 phosphorylation in locomotor activity generation.Nigral GFRα1 infusion in aged rats increases locomotor activity, nigral tyrosine hydroxylase, and dopamine content in synchronicity.Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats.Glial cell line-derived neurotrophic factor gene therapy ameliorates chronic hyperprolactinemia in senile rats.Role of BDNF and GDNF in drug reward and relapse: a reviewRetrograde axonal transport of glial cell line-derived neurotrophic factor in the adult nigrostriatal system suggests a trophic role in the adult.Dichotomy of tyrosine hydroxylase and dopamine regulation between somatodendritic and terminal field areas of nigrostriatal and mesoaccumbens pathways.Protection by glia-conditioned medium in a cell model of Huntington diseaseAdenoviral vector-mediated delivery of glial cell line-derived neurotrophic factor provides neuroprotection in the aged parkinsonian rat.Prospects for the treatment of Parkinson's disease using neurotrophic factors.Endogenous GDNF in ventral tegmental area and nucleus accumbens does not play a role in the incubation of heroin cravingViral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington's diseaseStriatal infusion of glial conditioned medium diminishes huntingtin pathology in r6/1 mice.Methyl 3,4-dihydroxybenzoate promotes neurite outgrowth of cortical neurons cultured in vitroHuntington's Disease: From Mutant Huntingtin Protein to Neurotrophic Factor Therapy.Neurorestoration.Evoked dopamine overflow is augmented in the striatum of calcitriol treated rats.Methodology and effects of repeated intranasal delivery of DNSP-11 in a rat model of Parkinson's disease.Transplantation of fetal kidney cells: neuroprotection and neuroregeneration.Potential drugs and methods for preventing or delaying the progression of Huntington's disease.Initiation of calorie restriction in middle-aged male rats attenuates aging-related motoric decline and bradykinesia without increased striatal dopamine.Gene therapy with AAV2-CDNF provides functional benefits in a rat model of Parkinson's diseaseCell-replacement and gene-therapy strategies for Parkinson's and Alzheimer's disease.Melatonin-based therapeutics for neuroprotection in stroke.Transcription factor Six2 mediates the protection of GDNF on 6-OHDA lesioned dopaminergic neurons by regulating Smurf1 expression.Exercise-Mediated Increase in Nigral Tyrosine Hydroxylase Is Accompanied by Increased Nigral GFR-α1 and EAAC1 Expression in Aging RatsCDNF protects the nigrostriatal dopamine system and promotes recovery after MPTP treatment in mice.Glial cells as players in parkinsonism: the "good," the "bad," and the "mysterious" glia.Glial cell line-derived neurotrophic factor partially ameliorates motor symptoms without slowing neurodegeneration in mice with respiratory chain-deficient dopamine neurons.Comparative study of the neurotrophic effects elicited by VEGF-B and GDNF in preclinical in vivo models of Parkinson's disease.Dynamic changes in dopamine neuron function after DNSP-11 treatment: effects in vivo and increased ERK 1/2 phosphorylation in vitro.
P2860
Q24682581-54D32094-4B7D-429D-9211-6B2549A1F0A8Q27309907-4D405D56-6B32-492A-8337-A8582E252CC1Q27320553-C2D52D54-322A-4845-9E64-540737C25DA1Q28088320-D47C13CF-771F-4F7B-9475-9E58A2C484A2Q28274130-10F436DA-C750-405C-A8EB-F4D40DDD34C0Q28591458-92007203-8AA4-4E01-B669-3E0BD21B7DE8Q28748465-98AB4E14-5960-4663-93D9-AB395E609D3FQ30666545-4E8C7F5D-056E-41AA-BD3B-31CD2589B84DQ31900813-6F1FD6D8-575B-49FD-B336-57BD0BBE5530Q33520922-63718112-A8AB-43E7-82F4-525DD6507F44Q33679788-9191CFC2-03CE-425D-A888-6AFF2CD21BC6Q33745707-424940D6-5BC6-4514-834C-9E53EA868509Q33787660-703CD309-7240-467A-AAA4-B3E9B65EB081Q33939940-85A4E374-1A78-4F55-8CC6-D47D7EDE46E9Q33964044-C509D4BB-14ED-4EAF-B04D-3BD42190B363Q34126665-6C5163B4-DA7E-478F-87C2-AD181302AA1BQ34392509-E1CA46CB-5D7B-4D03-B61D-4449B9249E5BQ34434662-C2A6D45B-BB9A-488F-B5C0-53F85852C3A2Q34515354-874DD7C7-FDFF-4C9B-BF11-60A28974DDA6Q34685643-B3E4C119-181B-4089-BDFE-2B6BE8189B1DQ34695123-4D3287F6-FA6C-4765-8758-7499A6583635Q34998578-BF1E8563-D5A2-438F-861B-AF52D771CF41Q35123777-EA6931D7-BEA8-448B-9AFC-38F00FD1D64DQ35158643-81A50D3B-4A7A-4EE0-8C6D-628B67EE1714Q35631869-DCCC64BD-48E1-493F-BA48-00114A45473AQ35713602-DB2DB17D-6B0C-4D39-9F23-64E5CDEF4B4DQ35847142-47E027B0-0DB6-4933-9B22-3D92EB0762F4Q36079544-51B76502-E130-42F4-93B2-196C6DF32895Q36142706-75549528-2E8C-4C14-92BE-7AF5A9C88C9BQ36396068-82D65CD6-AF1F-4D9C-BE1E-F649253E6B70Q36713101-2BCB50F6-714D-4C1C-82D5-35885A06F8B8Q36883772-87D2F899-A864-455D-A688-09CF432263F8Q36913537-AA57ADDD-628A-43ED-B030-3191402E3ECEQ37030300-5E9BC133-DD83-47E9-9249-83AC835BF346Q37051146-66D4C03F-22BC-45F5-A2E9-0371F1B562F2Q37121244-3295077C-8D8F-432D-94D1-20279C691BF2Q37333346-C545EF6F-08F6-4E5D-A56A-17C35062427EQ37466357-068452D3-8539-48C1-A36E-9311B752E5E4Q37582397-090D1751-3DDB-4846-B37A-E30040860AEEQ37706984-3D229CBD-8BC6-4972-AD01-23480F7080C4
P2860
Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
Glial cell line-derived neurot ...... dopaminergic neurons in vivo.
@en
type
label
Glial cell line-derived neurot ...... dopaminergic neurons in vivo.
@en
prefLabel
Glial cell line-derived neurot ...... dopaminergic neurons in vivo.
@en
P2093
P1433
P1476
Glial cell line-derived neurot ...... dopaminergic neurons in vivo.
@en
P2093
Bowenkamp K
Gerhardt GA
P304
P356
10.1016/0304-3940(94)90218-6
P407
P577
1994-11-01T00:00:00Z